

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 5966-01-RG	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/070530	
INTERNATIONAL APPLICATION NO. PCT/US00/17037		INTERNATIONAL FILING DATE 21 June 2001		PRIORITY DATE CLAIMED 15 September 1999	
TITLE OF INVENTION PTERIDINONES AS KINASE INHIBITORS					
APPLICANT(S) FOR DO/EO/US DENNY, William Alexander; DOBRUSIN, Ellen Myra; KRAMER, James Bernard; MCNAMARA, Dennis Joseph; REWCASTLE, Gordon William; SHOWALTER, Howard Daniel Hollis; TOOGOOD, Peter Laurence					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto.b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none">11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input type="checkbox"/> A FIRST preliminary amendment.14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.15. <input type="checkbox"/> A substitute specification.16. <input type="checkbox"/> A change of power of attorney and/or address letter.17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).20. <input checked="" type="checkbox"/> Other items or information: International Search Report (PCT/ISA/210) International Preliminary Examination Report (PCT/IPEA/409) Certificate of Mailing by Express Mail					

EXPRESS MAIL NO. EF378139439US
DOCKET NO. 5966-01-RG

U.S. APPLICATION NO. 10/070530 INTERNATIONAL APPLICATION NO. PCT/US00/17037				ATTORNEY'S DOCKET NUMBER 5966-01-RG																					
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY																					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	860.00																				
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>22 - 20 =</td> <td>2</td> <td>x \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>10 - 3 =</td> <td>7</td> <td>x \$80.00</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$270.00</td> </tr> <tr> <td colspan="3">TOTAL OF ABOVE CALCULATIONS =</td> <td></td> </tr> </tbody> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	22 - 20 =	2	x \$18.00	Independent claims	10 - 3 =	7	x \$80.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	TOTAL OF ABOVE CALCULATIONS =				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																						
Total claims	22 - 20 =	2	x \$18.00																						
Independent claims	10 - 3 =	7	x \$80.00																						
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00																						
TOTAL OF ABOVE CALCULATIONS =																									
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	36.00																				
SUBTOTAL =				\$	560.00																				
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	5,400.00																				
TOTAL NATIONAL FEE =				\$	6,986.00																				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	6,986.00																				
TOTAL FEES ENCLOSED =				\$	6,986.00																				
				Amount to be refunded:	\$																				
				charged:	\$																				
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>23-0455</u> in the amount of \$ <u>6,986.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0455</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.																									
SEND ALL CORRESPONDENCE TO: Rosanne Goodman, Ph.D. Warner-Lambert Company Patent Department 2800 Plymouth Road Ann Arbor, Michigan 48105 Telephone: (734) 622-4182 Facsimile: (734) 622-1553																									
<div style="display: inline-block; text-align: center;"> SIGNATURE </div> <div style="display: inline-block; text-align: center; margin-top: 10px;"> <u>Rosanne Goodman, Ph.D.</u> NAME </div> <div style="display: inline-block; text-align: center; margin-top: 10px;"> <u>32,534</u> REGISTRATION NUMBER </div>																									

10/070530

JC19 Rec'd PGT/PTO 06 MAR 2002

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s): William Alexander Denny, et al.			Docket No. 5966-01-RG
Serial No.	Filing Date	Examiner	Group Art
Invention: PTERIDINONES AS KINASE INHIBITORS			
I hereby certify that this <u>Patent Application for Filing Under 35 U.S.C. 371</u> (Identify type of correspondence)			
Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on <u>March 6, 2002</u> (Date)			
Linda A. Zerby (Typed or Printed Name of Person Mailing Correspondence)			
<u>Linda A. Zerby</u> (Signature of Person Mailing Correspondence)			
EF378139439US (“Express Mail” Mailing Label Number)			
Note: Each paper must have its own certificate of mailing			

EXPRESS MAIL NO. EF378139439US
DOCKET NO. 5966-01-RG